Eliem Therapeutics

Climb Bio ascends from Eliem legacy, buying IgA antibody for $9M

Eliem Therapeutics is continuing its transformation into an immune-mediated company by paying $9 million for a Chinese biotech’s preclinical antibody.

James Waldron Jan 9, 2025 10:07am

Paragliding with Mount Rainier in the background

Cell-focused Sana scoops first CSO—Chutes & Ladders

Aug 30, 2024 8:30am

Double autoimmune acquisitions as Century, Eliem pick up peers

Apr 11, 2024 9:06am

Eliem cuts in on Tango, proposing acquisition after review

Mar 19, 2024 10:57am

Eliem shuts down final drug program 5 months after major layoffs

Jul 20, 2023 9:05am

graphic image of five staffers leaving a door labeled closed below a sign labeled jobs

Eliem axes depression drug, lays off 55% of team to stretch cash

Feb 10, 2023 6:00am